Stoke Therapeutics
Stoke Therapeutics Logo
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company focused on developing antisense oligonucleotide medicines to increase target gene expression and treat diseases caused by loss of protein function. Utilizing its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, the company develops RNA-based therapies to selectively restore protein levels. Its lead programs include STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy, along with additional research targeting haploinsufficiency diseases of the central nervous system and eye. Stoke Therapeutics collaborates with other pharmaceutical companies to advance RNA-based medicines.
Address
45 Wiggins Avenue,
Bedford, 01730
United States
Year founded
2014
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
